Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of “Hold” by Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has earned an average recommendation of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.06.

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. JPMorgan Chase & Co. reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a report on Monday, August 17th.

Recursion Pharmaceuticals Stock Down 7.3%

Shares of RXRX traded down $0.26 during mid-day trading on Monday, reaching $3.25. The company had a trading volume of 5,528,894 shares, compared to its average volume of 18,167,123. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -3.11 and a beta of 1.03. The firm has a 50-day moving average price of $3.30 and a 200 day moving average price of $3.36. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same period last year, the business earned ($0.41) EPS. On average, sell-side analysts forecast that Recursion Pharmaceuticals will post -0.92 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total transaction of $97,500.00. Following the transaction, the director owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the sale, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,937 shares of company stock worth $478,874 over the last ninety days. 6.65% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $31,000. Integral Investment Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $39,000. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $41,000. MQS Management LLC purchased a new stake in Recursion Pharmaceuticals during the first quarter valued at $41,000. Finally, Fund Advisors of America Inc FL bought a new position in Recursion Pharmaceuticals in the second quarter valued at about $45,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.